首页> 美国卫生研究院文献>Future Science OA >Impact of serum levels of IL-18 and soluble IL-2 receptor on the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP regimen

【2h】

Impact of serum levels of IL-18 and soluble IL-2 receptor on the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP regimen

机译：血清IL-18和可溶性IL-2受体水平对R-CHOP方案治疗弥漫性大B细胞淋巴瘤患者临床结局的影响

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Aim & methods:To assess the impact of pretreatment serum levels of IL-18 and soluble IL-2 receptor (sIL-2R) on the clinical outcome of patients with diffuse large B-cell lymphoma treated with an R-CHOP protocol. Total 73 patients were included.

机译：目的和方法：评估预处理的血清IL-18和可溶性IL-2受体（sIL-2R）水平对使用R-CHOP方案治疗的弥漫性大B细胞淋巴瘤患者的临床结局的影响。总共包括73名患者。

著录项

期刊名称 Future Science OA
作者
Hussein M Khaled; Thoraya M Abdelhamid; Fouad M Abu-Taleb; Niveen M El-Hifnawi; Ahmad B Waley;
展开▼
作者单位

展开▼
年(卷),期 2019(5),9
年度 2019
页码 FSO414
总页数 11
原文格式 PDF
正文语种
中图分类情报学;
关键词
入库时间 2022-08-17 12:10:30

相似文献

外文文献
中文文献
专利

1. Serum Soluble Tumor Necrosis Factor Receptor 1 Level is Associated with the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with the CHOP or R-CHOP Regimen [J] . Naoe Goto, Hisashi Tsurumi, Masao Takemura, Journal of clinical and experimental hematopathology : . 2014,第2期

机译：血清可溶性肿瘤坏死因子受体1水平与CHOP或R-CHOP方案治疗的弥漫性大型B细胞淋巴瘤患者的预后相关
2. Serum Soluble Tumor Necrosis Factor Receptor 1 Level is Associated with the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with the CHOP or R-CHOP Regimen [J] . Naoe Goto, Hisashi Tsurumi, Masao Takemura, Journal of clinical and experimental hematopathology : . 2014,第2期

机译：血清可溶性肿瘤坏死因子受体1水平与CHOP或R-CHOP方案治疗的弥漫性大型B细胞淋巴瘤患者的预后相关
3. Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen [J] . Nakamura Nobuhiko, Goto Naoe, Tsurumi Hisashi, European Journal of Haematology . 2013,第4期

机译：可溶性肿瘤坏死因子受体2的血清水平与接受R-CHOP方案治疗的弥漫性大B细胞淋巴瘤患者的预后相关
4. Clinical significance and expression of microRNA-21 in diffuse large B-cell lymphoma cell lines and serum of patients [C] . CHEN Wei-qun, LU Honf-da, KONG De-yong, 2011 Asia-Pacific Conference of tumor biology and medicine . 2011

机译：患者弥漫性大B细胞淋巴瘤细胞株和血清中microRNA-21的表达及临床意义
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. ABCG2 and NCF4 polymorphisms are associated with clinical outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP [O] . Duo Liu, Nan Wu, Haiming Sun, 2017

机译：ABCG2和NCF4多态性与接受R-CHOP治疗的弥漫性大B细胞淋巴瘤患者的临床结局相关
7. Serum Soluble Tumor Necrosis Factor Receptor 1 Level is Associated with the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with the CHOP or R-CHOP Regimen [O] . Naoe Goto, Hisashi Tsurumi, Masao Takemura, 2014

机译：血清可溶性肿瘤坏死因子受体1水平与用剁碎或R-CHOP方案治疗的弥漫性大B细胞淋巴瘤患者的结果相关

Impact of serum levels of IL-18 and soluble IL-2 receptor on the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP regimen

摘要

著录项

相似文献

相关主题

期刊订阅